LY3871801

· Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for LY3871801, covering 2026-04-23 to 2026-04-23. Get the full timeline:

Most recent: Clinical Trial Update: An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis [Phase 2]